Prognostic Factors Influencing Postoperative Survival in Patients With Neuroendocrine Carcinoma of the Bladder: A Population‐Based Study
Authors:
Open Access
- 10 March 2025
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 14 (5) , e70758
Abstract
Background: This study aimed to identify prognostic factors influencing survival in patients with bladder neuroendocrine carcinoma (NC).Methods: This study utilized the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015) to compare NC with urothelial carcinoma (UC). We evaluated the prognostic value of clinicopathological characteristics and survival outcomes for bladder NC patients. Multivariable Cox proportional hazard models and propensity score matching (PSM) were employed for analysis.Result: A total of 99,704 patients were included, with 603 in the NC group and 99,101 in the UC group. Compared with the UC group, the NC group was inclined to receive radical cystectomy (34.2% vs. 12.2%), radiation (25.0% vs. 4.6%) and chemotherapy (62.0% vs. 22.2%) as treatment options. Multivariate Cox regression analysis revealed higher overall survival (OS) and cancer‐specific survival (CSS) outcomes for NC patients who underwent radical cystectomy (HR = 0.569, 95% CI = 0.537–0.603, p < 0.001; HR = 0.531, 95% CI = 0.489–0.577, p < 0.001; respectively). To mitigate bias, a 1:1 propensity score‐matched analysis was performed on both groups, resulting in 1202 patients (n = 601 per group). Multivariate Cox regression analysis identified seven risk factors for OS and CSS: age at diagnosis, race, cT stage, cN stage, cM stage, histological type, and chemotherapy. Additionally, surgery of the primary site was a prognostic factor for OS. A better prognosis was observed for NC patients who underwent radical cystectomy compared to those who did not. NC patients who only received radical cystectomy have a better prognosis in both OS (log‐rank p = 0.002) and CSS (log‐rank p = 0.009) compared with those who only received radiotherapy.Conclusion: Age, race, TNM stage, chemotherapy, and surgery were identified as independent predictors of bladder NC patients. Radical cystectomy may represent the optimal therapeutic approach to improve the prognosis of NC patients.Keywords
This publication has 37 references indexed in Scilit:
- Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to TherapyJournal of Thoracic Oncology, 2015
- Risk Factors, Therapy and Survival Outcomes of Small Cell and Large Cell Neuroendocrine Carcinoma of Urinary BladderRare Tumors, 2014
- Large Cell Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and ReviewCurrent Urology, 2014
- Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer CenterEuropean Urology, 2013
- Inverse p16 and p63 Expression in Small Cell Carcinoma and High-Grade Urothelial Cell Carcinoma of the Urinary BladderInternational Journal of Surgical Pathology, 2010
- Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial CancerJournal of Clinical Oncology, 2009
- Small cell carcinoma of the urinary bladderCancer, 2005
- Small cell carcinoma of the urinary bladderCancer, 2004
- EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCEJournal of Urology, 2004
- Small Cell Carcinoma of the Urinary BladderEuropean Urology, 2001